Share

June 2016; 3 (3) ArticleOpen Access

Clinical utility of testing AQP4-IgG in CSF

Guidance for physicians

Masoud Majed, James P. Fryer, Andrew McKeon, Vanda A. Lennon, Sean J. Pittock
First published April 20, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000231
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2288

Share

Article Information

vol. 3 no. 3 e231
DOI: 
https://doi.org/10.1212/NXI.0000000000000231
PubMed: 
27144221
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received November 25, 2015
  • Accepted in final form March 15, 2016
  • First Published April 20, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Masoud Majed, MD*,
    2. James P. Fryer, MS*,
    3. Andrew McKeon, MD,
    4. Vanda A. Lennon, MD, PhD and
    5. Sean J. Pittock, MD
  1. Masoud Majed, MD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. James P. Fryer, MS*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Andrew McKeon, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Medimmune, Inc

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Vanda A. Lennon, MD, PhD and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Vanda Lennon receives royalties from RSR/Kronus for sale of aquaporin-4 autoantibody testing kits and for commercial aquaporin-4 autoantibody testing performed outside Mayo Clinic.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH R01-NS065829,?CNS Demyelinating Autoimmunity Targeting Water Channel Complexes?. Principal Investigator: S.J. Pittock Co-Investigator: V.A. Lennon Years: 2010-2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. 1) RSR/Kronus for sale of aquaporin-4 autoantibody testing kits. 2) Non-Mayo sites performing “home brew” diagnostic testing for aquaporin-4 autoantibody.

    Royalty Payments, Technology or Inventions:

    1. Dr. Lennon has a potential financial interest in the technologies listed below: “Aquaporin-4 as an aid for cancer diagnosis”.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Sean J. Pittock, MD
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Dr. Pittock and Mayo Clinic have a financial interest in patents (#12/678,350 filed 2010 and #12/573,942 filed 2008) that relate to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker;

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Pittock has provided consultation to Alexion Pharmaceuticals, Medimmune and Chugai Pharma USA but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Pittock has received a research grant from Alexion pharmaceuticals for his investigator-initiated study entitled

    Research Support, Government Entities:

    1. RO1 NS065829-01

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Guthy Jackson Charitable Foundation grant for NMO research

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Laboratory Medicine and Pathology (M.M., J.P.F., A.M., V.A.L., S.J.P.), Neurology (A.M., V.A.L., S.J.P.), and Immunology (V.A.L.), Mayo Clinic, Rochester, MN.
  1. Correspondence to Dr. Pittock: pittock.sean{at}mayo.edu
View Full Text

Article usage

Article usage: April 2016 to April 2022

AbstractFullPdfSource
Apr 20161371816Highwire
May 201618461785Highwire
May 2016013161pmc
Jun 201643036114Highwire
Jun 201605332pmc
Jul 20169038641Highwire
Jul 201605329pmc
Aug 2016752229Highwire
Aug 201604145pmc
Sep 2016321220Highwire
Sep 201605132pmc
Oct 201633722Highwire
Oct 201604221pmc
Nov 201624327Highwire
Nov 201604817pmc
Dec 201620635Highwire
Dec 201604110pmc
Jan 201747422Highwire
Jan 201705223pmc
Feb 201718314Highwire
Feb 201706218pmc
Mar 201716627Highwire
Mar 201706021pmc
Apr 2017151320Highwire
Apr 2017104243pmc
May 201719910Highwire
May 2017104455pmc
Jun 201714411Highwire
Jun 2017215765pmc
Jul 20178215Highwire
Jul 201774245pmc
Aug 20179312Highwire
Aug 2017176875pmc
Sep 20179417Highwire
Sep 2017136469pmc
Oct 201711319Highwire
Oct 2017165153pmc
Nov 201714213Highwire
Nov 2017116570pmc
Dec 20170518Highwire
Jan 201822822Highwire
Feb 20182817Highwire
Mar 201811515Highwire
Apr 201821414Highwire
Apr 201824957pmc
May 201862316Highwire
Jun 20181269Highwire
Jun 201844549pmc
Jul 20181335Highwire
Aug 20183267Highwire
Aug 201867278pmc
Sep 201803506Highwire
Oct 201814999Highwire
Nov 201805503Highwire
Dec 2018076310Highwire
Jan 201941977Highwire
Feb 2019816712Highwire
Mar 20193257Highwire
Apr 20196810Highwire
May 201954214Highwire
Jun 201953316Highwire
Jul 20198187Highwire
Aug 201941210Highwire
Sep 201941610Highwire
Oct 201951712Highwire
Nov 2019162312Highwire
Dec 201923811Highwire
Jan 20203239Highwire
Feb 2020123112Highwire
Mar 202013016Highwire
Apr 202022516Highwire
May 202024622Highwire
Jun 202032821Highwire
Jul 20201299Highwire
Aug 202074325Highwire
Sep 202064917Highwire
Oct 202045320Highwire
Nov 202033115Highwire
Dec 202084730Highwire
Jan 202122519Highwire
Feb 202142622Highwire
Mar 202113313Highwire
Apr 202161612Highwire
May 202144111Highwire
Jun 2021112716Highwire
Jul 202163218Highwire
Aug 20216305Highwire
Sep 202141714Highwire
Oct 202162825Highwire
Nov 202132821Highwire
Dec 202123818Highwire
Jan 202222618Highwire
Feb 202222616Highwire
Mar 202252919Highwire
Apr 202223913Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement